1.12
-0.03
(-2.61%)
May 17 - Close
NASDAQ
real-time data -
Disclaimer
Currency in USD
| Range | 1.12 - 1.16 |
| 52 week | 0.91 - 2.99 |
| Open | 1.15 |
| Vol / Avg. | 930,253.00/674,830.00 |
| Mkt cap | 146.08M |
| P/E | - |
| Div/yield | - |
| EPS | -0.49 |
| Shares | 130.43M |
| Beta | 0.99 |
| Inst. own | 33% |
Events
Jul 29, 2013
Q2 2013 Geron Earnings Release
Jun 13, 2013
Geron at 18th Congress of European Hematology Association
May 22, 2013
Geron 2013 Annual Meeting of Stockholders
- 5:00PM EDT -
May 1, 2013
Geron at Needham Healthcare Conference -
May 1, 2013
Q1 2013 Geron Earnings Release
Apr 26, 2013
Q1 2013 Geron Earnings Conference Call -
Mar 13, 2013
Q4 2012 Geron Earnings Conference Call -
Mar 6, 2013
Geron at Cowen Health Care Conference -
|
More events from DailyFinance »
|
Key stats and ratios
| Q1 (Mar '13) | 2012 | |
| Net profit margin | -1555.16% | -2542.67% |
| Operating margin | -1566.67% | -2648.87% |
| EBITD margin | - | -2518.49% |
| Return on average assets | -52.25% | -53.02% |
| Return on average equity | -59.02% | -59.31% |
| Employees | 105 | - |
| Carbon Disclosure Rating | - | - |
Address
149 Commonwealth Drive
MENLO PARK, CA 94025
United States - Map
+1-650-4737700 (Phone)
+1-650-4737750 (Fax)
MENLO PARK, CA 94025
United States - Map
+1-650-4737700 (Phone)
+1-650-4737750 (Fax)
Website links
External links
Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Research Reports - Reuters
Discussion Group - Google Finance
Volume delayed by 15 mins.
Advertisement
Description
Geron Corporation (Geron) is a biopharmaceutical company developing therapies for cancer. The Company has two product candidates in clinical development, imetelstat and GRN1005. Imetelstat is a telomerase inhibitor that is being evaluated in four Phase 2 clinical trials: metastatic breast cancer, advanced non-small cell lung cancer, essential thrombocythemia and multiple myeloma. GRN1005 is a peptide-drug conjugate that is designed to transport a anti-cancer drug, paclitaxel, across the blood-brain barrier by targeting low-density lipoprotein receptor-related proteins (LRPs), specifically LRP-1. GRN1005 is being evaluated in two Phase 2 clinical trials: brain metastases arising from breast cancer and brain metastases arising from non-small cell lung cancer.
Officers and directors
| Hoyoung Huh M.D., Ph.D. | Chairman of the Board | |
| John A. Scarlett M.D. | President, Chief Executive Officer, Director | |
| Olivia K. Bloom | Chief Financial Officer, Senior Vice President, Treasurer, Principal Financial and Accounting Officer | |
| Stephen N. Rosenfield J.D. | Executive Vice President, General Counsel and Corporate Secretary | |
| Andrew J. Grethlein Ph.D. | Executive Vice President - Technical Operations | |
| Melissa A. Kelly Behrs | Senior Vice President - Portfolio and Alliance Management | |
| Craig C. Parker | Senior Vice President - Corporate Development | |
| Daniel M. Bradbury | Director | |
| Susan M. Molineaux Ph.D. | Director | |
| Karin Eastham CPA | Independent Director |